"We are deeply honored and proud to stand on the highest podium in China's science and technology field." Yesterday, Shenzhen Jingfeng Medical Technology Co., Ltd., as one of the main completion units, won the second prize of the National Science and Technology Progress Award for the "Innovation, Promotion and Application of Precision and Minimally Invasive Intelligent Diagnosis and Treatment Technology for bladder cancer" project. Wang Jianchen, its founder, chairman and CEO, excitedly told the reporter, "This award is the recognition of our scientific and technological innovation achievements and strength by the party and the country, and will also encourage us to continue to adhere to independent innovation, increase investment in research and development, deepen the collaborative integration of industry, university, research and application, promote more scientific and technological achievements into practical productivity, benefit more patients, and contribute to the realization of healthy China 2030." The reporter learned that the project of "Innovation and promotion of precision and minimally invasive intelligent diagnosis and treatment technology for bladder cancer", which was awarded this time, was jointly completed by Sun Yixian Memorial Hospital of Sun Yat sen University, Shenzhen Jingfeng Medical Technology Co., Ltd., Guangzhou Benchmark Medical Co., Ltd., and Savison (Guangzhou) Medical Technology Service Co., Ltd. The technology has realized non-invasive early diagnosis, accurate preoperative tumor staging A "Chinese plan" for bladder infusion has been developed, which includes minimally invasive functional surgery, rapid postoperative recovery, and localization of endoscopic surgical robots. At present, the research results have been extended to more than 600 hospitals nationwide, which has comprehensively improved the level of accurate diagnosis and treatment of bladder cancer in China. For a long time, the market of laparoscopic surgical robots in China has been monopolized by foreign brands, and the high prices of equipment and consumables have become an important factor restricting the popularization of robotic surgery technology in China. In the "minimally invasive and accurate diagnosis and treatment system for bladder cancer", the endoscopic surgery robot treatment scheme provided by Jingfeng Medical has changed the operation mode of bladder cancer in the domestic first minimally invasive and function preserving series of operations for bladder cancer, achieving precise resection, precise reconstruction, good surgical effect, rapid postoperative recovery, and successful domestic substitution. (Lai Xin She)